The Microdosing Approach Project

The development of new drugs is becoming an ever-increasingly complex and expensive process for pharmaceutical companies.

Progress of this project has been reported in many articles, presentations and circulations, including in special sessions or workshops of the FIP Pharmaceutical Sciences World Congress (PSWC) in April 2007 in Amsterdam NL, and the EUFEPS Conference on Optimising Drug Discovery and Development: Integrating Systems Approaches into Pharmaceutical Sciences in December 2007 in Basel CH. A new outcomes workshop is scheduled for June 16 2008 in Bad Homburg DE. For information and registration procedure (no charge), click

NEW!
EUFEPS and EUMAPP Workshop Microdosing in Drug Development: Current Status and Future Perspectives on June 16, 2008

Human microdosing is a new concept, in drug development, where one or more drug candidates are directly taken into human at trace doses in order to obtain early useful (PK) information. Such studies are, however, dependent on ultra-sensitive analytical techniques to follow the fate of a trace drug dose in the human body.

The European Union Microdose AMS Partnership Programme (EUMAPP), coordinated by XCELERON Ltd and funded by the European Commission, gathers together 10 organisations from 5 different countries (United Kingdom, Sweden, The Netherlands, France and Poland) towards the certification of high and low voltage Accelerator Mass Spectrometry technique (AMS) as the most accurate, reproducible and appropriate analytical methodologies for all measurements required by microdosing studies.

Download Background Paper in PDF, including scope, aim and focus of EUMAPP

EUMAPP Ad

From Parliament Magazine January 2007 (238/07)

Last updated April 8, 2008